Xynomic Closes $191.6 Million Merger with Bison Capital; Now Listed on Nasdaq Exchange
publication date: May 15, 2019
Xynomic Pharma has closed its business combination with Bison Capital Acquisition, becoming a wholly-owned subsidiary of BCAC. BCAC, which will change its name to Xynomic, will issue 42,860,772 new common shares of stock to Xynomic’s shareholders, worth $191.6 million. Another $55 million in shares will be available to Xynomic shareholders if certain objectives are met. Xynomic, founded in 2016, is headquartered in the US with operations in Raleigh, North Carolina and Shanghai. The company is developing three in-licensed novel oncology therapeutics in the US, Europe and China. More details....
Stock Symbol: (NSDQ: BCAC)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.